Future of polio vaccines

References

• Iwasaki A, Welker R, Mueller S et al. Immunofluorescence analysis of poliovirus receptor expression in Peyer’s patches of humans, primates, and CD155 transgenic mice: implications for poliovirus infection. J. Infect. Dis.186, 585–592 (2002).
   PubMed Web of Science ®Google Scholar
• Bodian D. Emerging concept of poliomyelitis infection. Science122, 105–108 (1955).
   PubMed Web of Science ®Google Scholar
• Bodian D, Howe HA. An experimental study of the role of neurones in the dissemination of poliomyelitis virus in the nervous system. Brain63, 135 (1940).
   Google Scholar
• Jubelt B, Gallez-Hawkins G, Narayan O, Johnson RT. Pathogenesis of human poliovirus infection in mice. I. Clinical and pathological studies. J. Neuropathol. Exp. Neurol.39(2), 138–148 (1980).
   PubMed Web of Science ®Google Scholar
• Ren R, Racaniello VR. Poliovirus spreads from muscle to the central nervous system by neural pathways. J. Infect. Dis.166, 747–752 (1992).
   PubMed Web of Science ®Google Scholar
• Sabin AB. Behavior of chimpanzee-avirulent poliomyelitis viruses in experimentally infected human volunteers. Clin. Lab. Sci.230(1), 1–8 (1955).
   Google Scholar
• Horstmann DM, Paul JR. The incubation period in human poliomyelitis and its implications. JAMA135, 11 (1947).
   PubMed Web of Science ®Google Scholar
• Melnick JL, Ledinko N. Social serology: antibody levels in a normal young population during an epidemic of poliomyelitis. Am. J. Hyg.54(3), 354–382 (1951).
   PubMedGoogle Scholar
• Nathanson N, Martin JR. The epidemiology of poliomyelitis: enigmas surrounding its appearance and disappearance. Am. J. Epidemiol.110, 672–692 (1979).
   PubMed Web of Science ®Google Scholar
• Anderson GW, Anderson G, Skaar A, Sandler F. Poliomyelitis in pregnancy. Am. J. Hyg.55, 127–139 (1952).
   PubMedGoogle Scholar
• Paffenbarger RS, Wilson VO. Previous tonsillectomy and current pregnancy as they affect risk of poliomyelitis. Ann. NY Acad. Sci.61, 856–868 (1955).
   PubMed Web of Science ®Google Scholar
• Weinstein L, Aycock WL, Feemster RF. Relation of sex, pregnancy, and menstruation to susceptibility in poliomyelitis. N. Engl. J. Med.245, 54–58 (1951).
   PubMed Web of Science ®Google Scholar
• Davis LE, Bodian D, Price D, Butler IJ, Vickers JH. Chronic progressive poliomyelitis secondary to vaccination of an immunodeficient child. N. Engl. J. Med.297, 241–245 (1977).
   PubMed Web of Science ®Google Scholar
• Wyatt HV. Poliomyelitis in hypogammaglobulinemics. J. Infect. Dis.128, 802–806 (1973).
   PubMed Web of Science ®Google Scholar
• Horstmann DM. Acute poliomyelitis. Relation of physical activity at the time of onset to the course of the disease. JAMA142, 236–241 (1950).
   PubMed Web of Science ®Google Scholar
• Russell WR. Paralytic poliomyelitis: the early symptoms, and the effect of physical activity on the course of disease. Br. Med. J.1, 465–471 (1949).
   PubMedGoogle Scholar
• Oshinsky DM. Polio: An American Story. Oxford University Press, Oxford, UK (2005).
   Google Scholar
• Enders JF, Weller TH, Robbins FC. Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissue. Science109, 85–87 (1949).
   PubMed Web of Science ®Google Scholar
• Francis T, Napier JA, Voight RB et al.Evaluation of the 1954 Field Trial of Poliomyelitis Vaccine. Final Report (Eds). Vaccine Evaluation Center, Department of Epidemiology, University of Michigan, MI, USA (1957).
   Google Scholar
• Sabin AB. Oral polio vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J. Infect. Dis.151, 420–436 (1985).
   PubMed Web of Science ®Google Scholar
• Alexander LN, Seward JF, Santibanez TA et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA292(14), 1696–1701 (2004).
   PubMed Web of Science ®Google Scholar
• Henderson DA, Witte JJ, Morris L, Langmuir AD. Paralytic disease associated with oral poliovaccines. JAMA190, 153–160 (1964).
   Web of Science ®Google Scholar
• McBean AM, Thoms ML, Albrecht P, Cuthie JC, Bernier R. The serologic response to oral polio vaccine and enhanced potency inactivated polio vaccines. Am. J. Epidemiol.128, 615–628 (1988).
   PubMed Web of Science ®Google Scholar
• Simoes EA, John TJ. The antibody response of seronegative infants to inactivated poliovirus vaccine of enhanced potency. Develop. Biol. Standard.14, 127–131 (1986).
   Google Scholar
• Sabin AB. Strategies for elimination of poliomyelitis in different parts of the world with use of oral poliovirus vaccine. Rev. Infect. Dis.6(Suppl. 2), S391–S396 (1984).
   PubMedGoogle Scholar
• Sabin AB. Perspectives on rapid elimination and ultimate global eradication of paralytic poliomyelitis caused by polioviruses. Eur. J. Epidemiol.7(2), 95–120 (1991).
   PubMed Web of Science ®Google Scholar
• Kew O, Morris-Glasgow V, Landaverde M et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science296(5566), 356–359 (2002).
   PubMed Web of Science ®Google Scholar
• CDC. Update on vaccine-derived polioviruses – worldwide, January 2006–August 2007. MMWR56(38), 996–1001 (2007).
   PubMedGoogle Scholar
• Adu F, Iber J, Bukbuk D et al. Isolation of recombinant type 2 vaccine-derived poliovirus (VDPV) from a Nigerian child. Virus Res.127(1), 17–25 (2007).
   PubMed Web of Science ®Google Scholar
• Korotkova EA, Park R, Cherkasova EA et al. Retrospective analysis of a local cessation of vaccination against poliomyelitis: a possible scenario for the future. J. Virol.77(23), 12460–12465 (2003).
   PubMed Web of Science ®Google Scholar
• Labadie K, Pelletier I, Saulnier A, Martin J, Colbere-Garapin F. Poliovirus mutants excreted by a chronically infected hypogammaglobulinemic patient establish persistent infections in human intestinal cells. Virology318(1), 66–78 (2004).
   PubMed Web of Science ®Google Scholar
• Blomqvist S, Savolainen C, Laine P et al. Characterization of a highly evolved vaccine-derived poliovirus type 3 isolated from sewage in Estonia. J. Virol.78(9), 4876–4883 (2004).
   PubMed Web of Science ®Google Scholar
• Shulman LM, Manor Y, Sofer D et al. Neurovirulent vaccine-derived polioviruses in sewage from highly immune populations. PLoS ONE1, e69 (2006).
   PubMed Web of Science ®Google Scholar
• Grassly NC, Fraser C, Wenger J et al. New strategies for the elimination of polio from India. Science314(5802), 1150–1153 (2006).
   PubMed Web of Science ®Google Scholar
• el-Sayed N, el-Gamal Y, Abbassy AA et al. Monovalent type 1 oral poliovirus vaccine in newborns. N. Engl. J. Med.359(16), 1655–1665 (2008).
   PubMed Web of Science ®Google Scholar
• Jenkins HE, Aylward RB, Gasasira A et al. Effectiveness of immunization against paralytic poliomyelitis in Nigeria. N. Engl. J. Med.359(16), 1666–1674 (2008).
   PubMed Web of Science ®Google Scholar
• Lasch EE, Abed Y, Abdulla K et al. Successful results of a program combining live and inactivated poliovirus vaccines to control poliomyelitis in Gaza. Rev. Infect. Dis.6(Suppl. 2), S467–S470 (1984).
   Google Scholar
• Dowdle WR, De Gourville E, Kew OM, Pallansch MA, Wood DJ. Polio eradication: the OPV paradox. Rev. Med. Virol.13(5), 277–291 (2003).
   PubMed Web of Science ®Google Scholar
• Cello J, Paul AV, Wimmer E. Chemical synthesis of poliovirus cDNA: generation of infectious virus in the absence of natural template. Science297(5583), 1016–1018 (2002).
   PubMed Web of Science ®Google Scholar
• Thompson KM, Tebbens RJ, Pallansch MA et al. The risks, costs, and benefits of possible future global policies for managing polioviruses. Am. J. Public Health98(7), 1322–1330 (2008).
   PubMed Web of Science ®Google Scholar
• Peart AF, Rhodes AJ et al. An outbreak of poliomyelitis in Canadian Eskimos in wintertime. Can. J. Public Health40(10), 405–419 (1949).
   PubMedGoogle Scholar
• Rhodes AJ, Chapman M. Some observations on interference between neurotropic viruses. Can. J. Res.27(6 Sect. E), 341–348 (1949).
   PubMed Web of Science ®Google Scholar
• Chumakov K, Ehrenfeld E. New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis. Clin. Infect. Dis.47(12), 1587–1592 (2008).
   PubMed Web of Science ®Google Scholar
• Ivanov AP, Dragunsky EM, Chumakov KM. 1,25-dihydroxyvitamin D3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice. J. Infect. Dis.193(4), 598–600 (2006).
   PubMed Web of Science ®Google Scholar
• De Palma AM, Purstinger G, Wimmer E et al. Potential use of antiviral agents in polio eradication. Emerg. Infect. Dis.14(4), 545–551 (2008).
   PubMed Web of Science ®Google Scholar
• Committee on Development of a Polio Antiviral and Its Potential Role in Global Poliomyelitis Eradication NRC. Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report. National Academies Press, Washington, DC, USA (2006).
   Google Scholar